In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed at $46.55 in the last session, down -1.77% from day before closing price of $47.39. In other words, the price has decreased by -$1.77 from its previous closing price. On the day, 0.61 million shares were traded. CRNX stock price reached its highest trading level at $47.355 during the session, while it also had its lowest trading level at $46.43.
Ratios:
We take a closer look at CRNX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.12 and its Current Ratio is at 15.12. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on July 10, 2025, initiated with a Neutral rating and assigned the stock a target price of $36.
On March 25, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $60.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 01 ’25 when Pizzuti Dana sold 5,000 shares for $45.02 per share. The transaction valued at 225,100 led to the insider holds 66,837 shares of the business.
DANA PIZZUTI bought 5,000 shares of CRNX for $227,800 on Dec 01 ’25. On Nov 03 ’25, another insider, Pizzuti Dana, who serves as the Chief Med and Dev Officer of the company, sold 5,000 shares for $42.66 each. As a result, the insider received 213,312 and left with 66,270 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 4417214976 and an Enterprise Value of 3374068224. For the stock, the TTM Price-to-Sale (P/S) ratio is 2887.07 while its Price-to-Book (P/B) ratio in mrq is 4.10. Its current Enterprise Value per Revenue stands at 2198.09 whereas that against EBITDA is -7.116.
Stock Price History:
The Beta on a monthly basis for CRNX is 0.20, which has changed by -0.12417686 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, CRNX has reached a high of $53.55, while it has fallen to a 52-week low of $24.10. The 50-Day Moving Average of the stock is 3.58%, while the 200-Day Moving Average is calculated to be 30.09%.
Shares Statistics:
According to the various share statistics, CRNX traded on average about 1.33M shares per day over the past 3-months and 942370 shares per day over the past 10 days. A total of 94.55M shares are outstanding, with a floating share count of 88.14M. Insiders hold about 7.12% of the company’s shares, while institutions hold 110.25% stake in the company. Shares short for CRNX as of 1765756800 were 14227298 with a Short Ratio of 10.68, compared to 1763078400 on 15921779. Therefore, it implies a Short% of Shares Outstanding of 14227298 and a Short% of Float of 17.040001.
Earnings Estimates
The firm’s stock currently is rated by 12.0 analysts. The consensus estimate for the next quarter is -$1.41, with high estimates of -$1.19 and low estimates of -$1.7.
Analysts are recommending an EPS of between -$4.07 and -$5.19 for the fiscal current year, implying an average EPS of -$4.95. EPS for the following year is -$5.22, with 12.0 analysts recommending between -$3.94 and -$7.04.
Revenue Estimates
For the next quarter, 12 analysts are estimating revenue of $6.58M. There is a high estimate of $11.1M for the next quarter, whereas the lowest estimate is $4.6M.
A total of 13 analysts have provided revenue estimates for CRNX’s current fiscal year. The highest revenue estimate was $9.54M, while the lowest revenue estimate was $2.5M, resulting in an average revenue estimate of $5.04M. In the same quarter a year ago, actual revenue was $1.04MBased on 13 analysts’ estimates, the company’s revenue will be $54.87M in the next fiscal year. The high estimate is $112.07M and the low estimate is $20.68M.
